Pēdējā atjaunošana :
22/08/2024
Infostab
Saraksti
Kopsavilkums
Meklēt saderības
Y-savienojuma saderības tabula
Literatūras saraksts
pētniecības grupas
valistab
plakāts
Savienojumi
sponsori
Autori
Lietošanas instrukcija
Newsletter
Cefepime dihydrochloride
Ķīmiskā uzbūve
Oriģinālais nosaukums
Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām
Aspime
Venecuēla
Avipim
Turcija
Axépim
Francija
Baxypime
Meksika
Cachepime
Indija
Cefalospim
Brazīlija
Cefemin
Kolumbija
Cefepem
Brazīlija
Cefepitax
Brazīlija
Cepim
Itālija
Cepimex
Itālija
Forcetex
Ēģipte
Maxcef
Brazīlija
Maxipime
Amerikas Savienotās Valstis, Austrija, Beļģija, Grieķija, Itālija, Kanāda, Kolumbija, Luksemburga, Peru, Polija, Portugāle, Somija, Spānija, Turcija, Ungārija, Vācija, Zviedrija
Nebamix
Peru
Olpelinol
Meksika
Pimcef
Peru
Pimerzen
Meksika
Roxipime
Turcija
Unisef
Turcija
Vipefime
Meksika
Literatūras saraksts : Cefepime dihydrochloride
tips
publicēšana
182
Žurnāls
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
251
Žurnāls
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
873
Žurnāls
Das Gupta V, Maswoswe J, Bailey RE.
Stability of cefepime hydrochloride dextrose in 5% dextrose injection and 0.9% sodium chloride injection.
Int J Pharm Compound 1997 ; 1: 435-436.
921
Žurnāls
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1046
Žurnāls
Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride in polypropylene syringes.
Am J Health-Syst Pharm 1999 ; 56: 1134.
1068
Žurnāls
Stewart JT, Warren FW, Maddox FC.
Stability of cefepime hydrochloride in polypropylene syringes at -20°C, 4°C and 22-24°C.
Am J Health-Syst Pharm 1999 ; 56: 457-459.
1290
Žurnāls
Williamson JC, Volles DF, Lynch PLM, Rogers PD, Haverstick DM.
Stability of cefepime in peritoneal dialysis solution.
Ann Pharmacotherapy 1999 ; 33: 906-909.
1410
Žurnāls
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1605
Žurnāls
Stewart JT, Maddox FC, Warren FW.
Stability of cefepime hydrochloride injection and metronidazole in polyvinyl chloride bags at 4°C and 22-24°C.
Hosp Pharm 2000 ; 35: 1057-1064.
1625
Žurnāls
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1626
Žurnāls
Ling J, Das Gupta V.
Stability of cefepime hydrochloride after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use.
Int J Pharm Compound 2001 ; 5: 151-152.
1648
Žurnāls
Schlesser V, Hecq J-D, Vanbeckbergen D, Jamart J, Galanti LM.
Effect of freezing, long-term storage, and microwave thawing on the stability of cefepime in 5% dextrose infusion polyvinyl chloride bags.
Int J Pharm Compound 2002 ; 6: 391-394.
1673
Žurnāls
Rabouan-Guyon M, Guet AF, Courtois PY, Barthes DMC.
Stability study of cefepime in different infusion solutions.
Int J Pharm 1997 ; 154: 185-190.
1712
Žurnāls
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713
Žurnāls
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721
Žurnāls
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754
Žurnāls
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1803
Žurnāls
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1834
Žurnāls
Trissel LA, Xu QA.
Stability of cefepime hydrochloride in autodose infusion system bags.
Ann Pharmacotherapy 2003 ; 37, 6: 804-807.
1945
Žurnāls
Elwell RJ, Volino LR, Frye RF.
Stability of cefepime in icodextrin peritoneal dialysis solution.
Ann Pharmacotherapy 2004 ; 38: 2041-2044.
1982
Žurnāls
Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042
Žurnāls
Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2046
Žurnāls
Sprauten PF, Beringer PM, Louie ST, Synold TW, Gill MA.
Stability and antibacterial activity of cefepime during continuous infusion.
Antimicrob Agents Chemother 2003 ; 47: 1991-1994.
2134
Žurnāls
Fubara JO, Notari RE.
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions.
J Pharm Sci 1998 ; 87, 12: 1572-1576.
2141
Žurnāls
Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2192
Žurnāls
Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2231
Žurnāls
de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247
Žurnāls
Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3254
Žurnāls
Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385
Žurnāls
Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3416
Žurnāls
Csaba M, Boddu,S.H.S , Churchwell M.D.
Physical compatibility of sodium citrate with alcohol and cefepime.
Am J Health-Syst Pharm 2013 ; 70: 932-937
3520
Laboratorija
Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3542
Žurnāls
Berti A.D, Hutson P.R, Schulz L.T, Webb A.P, Rose W.E.
Compatibility of cefepime and vancomycin during simulated Y-site administration of prolonged infusion
Am J Health-Syst Pharm 2015 ; 72:390-395
3548
Laboratorija
Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3549
Laboratorija
Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3643
Laboratorija
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3674
Laboratorija
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3827
plakāts
Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828
plakāts
Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829
plakāts
So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3879
Žurnāls
Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E.
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3948
Žurnāls
Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
4055
Žurnāls
Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145
Žurnāls
Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254
Žurnāls
D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4326
Žurnāls
Curti C, Harti Souab K, Lamy E, Mathias F, Bornet C, Guinard B, Fersing C, Primas N, Albanèse J, Vanelle P.
Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion.
Pharmazie 2019 ; 74: 357-362.
4411
Žurnāls
Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A.
Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
Int J Pharm Compound 2020 ;24,3:238-241.
4434
Žurnāls
Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440
Žurnāls
Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4465
Žurnāls
Foushee A, Meredith P, Fox Laura, Wilder A.
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4521
Žurnāls
Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528
Žurnāls
Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4634
Žurnāls
Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A.
Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Antibiotics 2022 ;11,4: 458
4801
Žurnāls
Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
Mentions Légales